The X-linked syndrome is a systemic autoinflammatory disease of undefined origin. It resists the classic therapeutic arsenal, but Janus kinase pathway inhibitors show promise as treatments.
New mouse models demonstrating how higher body temperature reduces levels of mevalonate kinase can serve as preclinical platforms to test the efficacy and safety of possible treatments.